RALEIGH – RedHill Biopharma is another step closer to getting one of its potential treatments for COVID-19 tested.
The Israeli company, which has its U.S. headquarters and commercial operations in Raleigh, got the green light to provide its investigational drug, RHB-107 (upamostat, WX-671), for testing in non-clinical studies against the coronavirus.
It’s part of an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
RHB-107 is a proprietary, first-in-class orally administered protease inhibitor targeting pancreatic cancer and inflammatory gastrointestinal diseases. According to RedHill, it presents a new, non-cytotoxic approach to cancer therapy.
The drug has already been studied in more than 300 people across 10 clinical studies, including two completed Phase 2 studies in oncology patients and several Phase 1 studies in healthy volunteers and oncology patients. RedHill said these studies helped establish the safety and tolerability of RHB-107 in humans.